Artificial Tears: Global Strategic Business Report

Global Artificial Tears Market to Reach $5.3 Billion by 2030

The global market for Artificial Tears estimated at US$3.5 Billion in the year 2022, is projected to reach a revised size of US$5.3 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2022-2030. Glycol-based, one of the segments analyzed in the report, is projected to record 4.5% CAGR and reach US$2.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cellulose-based segment is readjusted to a revised 5.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $964 Million, While China is Forecast to Grow at 10% CAGR

The Artificial Tears market in the U.S. is estimated at US$964 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 10% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.7% and 3.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Select Competitors (Total 49 Featured) -

• Abbott Medical Optics Inc.
• Akorn, Inc.
• Allergan, Inc.
• Bausch & Lomb Inc.
• Johnson & Johnson
• Novartis International AG

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year